Drugs / ASCRINVACUMAB
Trials 9
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT02116894 | Aug 2014 → Feb 2016 | colorectal cancer | Duke University | Completed | No outcome recorded |
| Phase 1 | NCT01337050 | Jul 2011 → Dec 2013 | neoplasm | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT00557856 | Nov 2007 → Mar 2013 | cancer | Pfizer | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT04984668 | Nov 2021 → Apr 2025 | cancer | Suzhou Kintor Pharmaceutical Inc | Unknown | No outcome recorded |
| Phase 1/2 | NCT03893695 | May 2019 → May 2022 | drug dependence, hepatocellular carcinoma | Suzhou Kintor Pharmaceutical Inc | Completed | No outcome recorded |
| Phase 24 trials · 2 missed | ||||||
| Phase 2 | NCT05178043 | Aug 2021 → Apr 2025 | hepatocellular carcinoma | Suzhou Kintor Pharmaceutical Inc | Unknown | No outcome recorded |
| Phase 2 | NCT01911273 | Oct 2013 → Jul 2014 | hepatocellular carcinoma | Pfizer | Terminated | No outcome recorded |
| Phase 2 | NCT01486368 | Jun 2012 → Apr 2014 | malignant pleural mesothelioma | NCIC Clinical Trials Group | Completed | Missed primary |
| Phase 2 | NCT01620970 | Mar 2012 → Jun 2013 | bladder transitional cell carcinoma | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | Completed | Missed primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ASCRINVACUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109295 ↗ |
| Known as | GT90001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05178043 ↗ |
| Known as | PF-03446962 | “GT90001 (also known as PF-03446962) is an anti-ALK-1 monoclonal antibody and has shown activity in hepatocellular carcinoma (HCC).” PMID 37858184 ↗ Oct 20238“PF 03446962 plus best supportive care (BSC)” NCT01911273 ↗ “PF 03446962 given by a 1 hour IV infusion.” NCT01337050 ↗ |
| Action | Inhibit | “suggesting in vivo inhibition of the ALK-1 pathway.” PMID 26655846 ↗ Dec 2015 |
| Modality | Monoclonal antibody | “PF-03446962, a fully human monoclonal antibody against activin receptor-like kinase-1” PMID 27329247 ↗ Jun 2016 |
| Route | Intravenous | “PF-03446962 was administered biweekly by intravenous infusion” PMID 26655846 ↗ Dec 2015 |
| Target | ACVRL1 | “anti-ALK-1” PMID 37858184 ↗ Oct 2023 |